Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep 20:7:375.
doi: 10.3389/fped.2019.00375. eCollection 2019.

Antifungal Drugs for Invasive Candida Infections (ICI) in Neonates: Future Perspectives

Iliana Bersani  1 , Fiammetta Piersigilli  1 , Bianca Maria Goffredo  2 , Alessandra Santisi  1 , Sara Cairoli  2 , Maria Paola Ronchetti  1 , Cinzia Auriti  1
Affiliations
Review

Antifungal Drugs for Invasive Candida Infections (ICI) in Neonates: Future Perspectives

Iliana Bersani et al. Front Pediatr. .

Abstract

Fungal infections may complicate the neonatal clinical course, and the spectrum of therapies for their treatment in the perinatal period is limited. Polyenes, Azoles and Echinocandins represent the three classes of antifungal drugs commonly used in the neonatal period. The present review provides an overview about the most recent therapeutic strategies for the treatment of fungal infections in neonates.

Keywords: azoles; candidemia; echinocandins; fungal infection; lock therapy; neonate; polyenes; sepsis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
AmB deoxycholate should be started at 1 mg/kg intravenous daily and can be increased up to 1.5 mg/Kg/die. An alternative option is liposomal AmB that should be started at 3–5 mg/kg daily. The addition of 5-flucytosine 25 mg/kg four times daily at should be considered as salvage therapy in patients not responsive to initial AmB therapy or with End Organ Dissemination (EOD). Fluconazole, 12 mg/kg daily, is recommended for Candida strains that are susceptible to fluconazole, in babies who had not a previous fluconazole prophylaxis. Algorithm for the initial treatment of Invasive Candida Infections in neonates [from (28), modified].
See this image and copyright information in PMC

References

    1. Cotter G, Kavanagh K. Adherence mechanisms of Candida albicans. Br J Biomed. Sci. (2000) 57:241–9. - PubMed
    1. Hube B, Naglik J. Extracellular hydrolases. In: Calderone R, editor. Candida and Candidiasis. Washington DC: ASM Press; (2002). p. 107.
    1. Arsenault AB, Bliss JM. Neonatal candidiasis: new insights into an old problem at a unique host-pathogen interface. Curr Fungal Infect Rep. (2015) 9:246–52. 10.1007/s12281-015-0238-x - DOI - PMC - PubMed
    1. Benjamin DK, Jr, Stoll BJ, Fanaroff AA, McDonald SA, Oh Higgins W, et al. National institute of child health and human development neonatal research network. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics. (2006) 117:84–92. 10.1542/peds.2004-2292 - DOI - PubMed
    1. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al. . (2002). Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics. 110:285–91. 10.1542/peds.110.2.285 - DOI - PubMed

LinkOut - more resources